Literature DB >> 15805578

Introduction to the background, principles, and state of the art in suicide gene therapy.

Ion Niculescu-Duvaz1, Caroline J Springer.   

Abstract

Gene therapy is defined as a technology that aims to modify the genetic component of cells to gain therapeutic benefits. Suicide gene therapy (or gene-directed enzyme prodrug therapy [GDEPT]) is a two-step treatment for cancer (especially, solid tumors). In the first step, a gene for a foreign enzyme is delivered to the tumor by a vector. Following the expression of the foreign enzyme, a prodrug is administered during the second step, which is selectively activated in the tumor. This article discusses the principles and the theorectical background of GDEPT. A special emphasis is put on enzyme/prodrug systems developed for GDEPT, the design of prodrugs and the kinetic of their activation, the types and the mechanisms of bystander effect and its immunological implications. The possible strategies to improve GDEPT are also discussed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15805578     DOI: 10.1385/MB:30:1:071

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  83 in total

Review 1.  Prodrug-activating systems in suicide gene therapy.

Authors:  C J Springer; I Niculescu-Duvaz
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy.

Authors:  R Marais; R A Spooner; S M Stribbling; Y Light; J Martin; C J Springer
Journal:  Nat Biotechnol       Date:  1997-12       Impact factor: 54.908

3.  Direct correlation between positron emission tomographic images of two reporter genes delivered by two distinct adenoviral vectors.

Authors:  S S Yaghoubi; L Wu; Q Liang; T Toyokuni; J R Barrio; M Namavari; N Satyamurthy; M E Phelps; H R Herschman; S S Gambhir
Journal:  Gene Ther       Date:  2001-07       Impact factor: 5.250

4.  Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines.

Authors:  K Imaizumi; Y Hasegawa; T Kawabe; N Emi; H Saito; K Naruse; K Shimokata
Journal:  Am J Respir Cell Mol Biol       Date:  1998-02       Impact factor: 6.914

5.  Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-alpha-peptide prodrugs.

Authors:  D A Hamstra; M Pagé; J Maybaum; A Rehemtulla
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

6.  Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.

Authors:  T Kammertoens; W Gelbmann; P Karle; K Alton; R Saller; B Salmons; W H Günzburg; W Uckert
Journal:  Cancer Gene Ther       Date:  2000-04       Impact factor: 5.987

7.  Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model.

Authors:  Z Huang; M K Raychowdhury; D J Waxman
Journal:  Cancer Gene Ther       Date:  2000-07       Impact factor: 5.987

Review 8.  Gap junctions: the "kiss of death" and the "kiss of life".

Authors:  A F Andrade-Rozental; R Rozental; M G Hopperstad; J K Wu; F D Vrionis; D C Spray
Journal:  Brain Res Brain Res Rev       Date:  2000-04

9.  Herpes simplex virus thymidine kinase gene therapy in experimental rat BT4C glioma model: effect of the percentage of thymidine kinase-positive glioma cells on treatment effect, survival time, and tissue reactions.

Authors:  A M Sandmair; M Turunen; K Tyynelä; S Loimas; P Vainio; R Vanninen; M Vapalahti; R Bjerkvig; J Jänne; S Ylä-Herttuala
Journal:  Cancer Gene Ther       Date:  2000-03       Impact factor: 5.987

10.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.

Authors:  B E Huber; E A Austin; C A Richards; S T Davis; S S Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

View more
  23 in total

Review 1.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

2.  Safeguarding nonhuman primate iPS cells with suicide genes.

Authors:  Bonan Zhong; Korashon L Watts; Jennifer L Gori; Martin E Wohlfahrt; Joerg Enssle; Jennifer E Adair; Hans-Peter Kiem
Journal:  Mol Ther       Date:  2011-05-17       Impact factor: 11.454

Review 3.  Progress and problems with the use of suicide genes for targeted cancer therapy.

Authors:  Zahra Karjoo; Xuguang Chen; Arash Hatefi
Journal:  Adv Drug Deliv Rev       Date:  2015-05-22       Impact factor: 15.470

Review 4.  Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.

Authors:  Andressa Ardiani; Adam J Johnson; Hongmei Ruan; Marilyn Sanchez-Bonilla; Kinta Serve; Margaret E Black
Journal:  Curr Gene Ther       Date:  2012-04-01       Impact factor: 4.391

Review 5.  Is cancer gene therapy an empty suit?

Authors:  Malcolm K Brenner; Stephen Gottschalk; Ann M Leen; Juan F Vera
Journal:  Lancet Oncol       Date:  2013-10       Impact factor: 41.316

6.  Plant thymidine kinase 1: a novel efficient suicide gene for malignant glioma therapy.

Authors:  Zahidul Khan; Wolfgang Knecht; Mette Willer; Elzbieta Rozpedowska; Peter Kristoffersen; Anders Ranegaard Clausen; Birgitte Munch-Petersen; Per M Almqvist; Zoran Gojkovic; Jure Piskur; Tomas J Ekström
Journal:  Neuro Oncol       Date:  2010-02-13       Impact factor: 12.300

7.  Apoptotic induction with bifunctional E.coli cytosine deaminase-uracil phosphoribosyltransferase mediated suicide gene therapy is synergized by curcumin treatment in vitro.

Authors:  P Gopinath; Siddhartha Sankar Ghosh
Journal:  Mol Biotechnol       Date:  2007-12-19       Impact factor: 2.695

Review 8.  Gene therapy: design and prospects for craniofacial regeneration.

Authors:  E L Scheller; P H Krebsbach
Journal:  J Dent Res       Date:  2009-07       Impact factor: 6.116

9.  Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.

Authors:  H Lu; C-S Chen; D J Waxman
Journal:  Cancer Gene Ther       Date:  2008-11-14       Impact factor: 5.987

Review 10.  Gene therapy in pancreatic cancer.

Authors:  Si-Xue Liu; Zhong-Sheng Xia; Ying-Qiang Zhong
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.